Kaido Kurrikoff, MSc, 2005, juh. Sulev Kõks. CCK2 retseptori geneetiline väljalülitamine vähendab mehaanilist tundlikkust ja pärsib hüperalgeesia teket närvikahjustusega hiirtel. Tartu

Kristel Vabrit, MSc, 2005, juh. Sulev Kõks. Võimalikud seosed tsütokiinide interleukiin 20 ja interleukiin 24 geenide polümorfismide ja naastulise psoriaasi kujunemise vahel. Tartu

Külli Kingo, PhD, 2005, juh. Sulev Kõks. The interleukin-10 family cytokines gene polymorphisms in plaque psoriasis. Tartu

Mario Plaas, MSc, 2005, juh. Sulev Kõks. Alfa-syn Ala30Pro punktmutatsiooniga ja beeta-syn deletsiooniga hiireliinide loomine: uued Parkinsoni haiguse mudelid. Tartu

Ranno Rätsep, MSc, 2005, juh. Sulev Kõks. Interleukiin-19 ja intereleukiin-20 haplotüüpide efektid naastulise psoriaasi avaldumisel. Tartu

Hendrik Luuk, MSc, 2004, juh. Sulev Kõks. Volframiini ja karboksüpeptidaas E koregulatsioon roti mandelkehas vastusena hirmuregulatsioonile ja interaktsioon rakukultuuris. Tartu

Mari-Anne Philips, MSc, 2004, juh. Sulev Kõks. Agressiivsete (SAL) ja mitte-agressiivsete (LAL) hiireliinide geeniekspressiooni diferentsiaalanalüüs hippokampuses.. Tartu

S. Kõks, K. Kingo, E. Vasar, H. Silm “Interleukin-19 subfamily of cytokines”, peatükk raamatus “Cytokine gene polymorphisms in multifactorial conditions”. CRC Press, in press.

S. Kõks, K. Kingo, E. Vasar, H. Silm “Psoriasis and cytokine polymorphisms”, peatükk raamatus “Cytokine gene polymorphisms in multifactorial conditions”. CRC Press, in press.

Abramov U, Vasar E, Kõks S. (2005) Altered behavioural effects of ethanol and increased voluntary ethanol consumption in mice lacking cck2 receptors. Behavioral Pharmacology 16 1:S19.

Areda T, Kõks S, Philips MA, Vasar E, Karis A, Asser T (2005) Alterations in opioid system of the rat brain after cat odor exposure. Neuroscience Letters 377:136-139.

Kingo K, Rätsep R, Kõks S, Karelson M, Silm H, Vasar E (2005) Influence of genetic polymorphisms on interleukin-10 mRNA expression and psoriasis susceptibility. Journal of Dermatological Science 37:111-113.

Koido K, Kõks S, Nikopensius T, Maron E, Altme S, Heinaste E, Vabrit K, Tammekivi V, Hallast P, Kurg A, Shlik J, Vasar V, Metspalu A, Vasar E (2005) Polymorphisms in wolframin (WFS1) gene are possibly related to increased risk for mood disorders. International Journal of Neuropsychopharmacology 8:235-244.

Kõks S, Kingo K, Vabrit K, Rätsep R, Karelson M, Silm H, Vasar E. (2005) Possible relations between the polymorphisms of the cytokines IL 19, IL 20 and IL 24 and plaque-type psoriasis. Genes and Immunity 6:407-415.

Kõks S, Nikopensius T, Koido K, Maron E, Altmäe S, Heinaste E, Vabrit K, Tammekivi V, Hallast P, Kurg A, Shlik J, Vasar V, Metspalu A, Vasar E. (2005) Analysis of SNP profiles in patients with major depressive disorder. International Journal of Neuropsychopharmacology. (In press, doi:10.1017/ S1461145705005468).

Luuk H, Toots U, Kõks S, Vasar E (2005) N-terminal domain of Wolframin interacts with carboxypeptidase E. European Neuropsychopharmacology 15:S5-S6.

Maron E, Kõks S, Nikopensius T, Altmae S, Heinaste E, Vabrit K, Tammekivi V, Hallast P, Koido K, Kurg A, Shlik J, Vasar V, Metspalu A, Vasar E (2005) Association and haplotype analaysis of 90 single-nucleotide polymorphisms in mood disorders. European Neuropsychopharmacology 15:S55-S56.

Maron E, Nikopensius T, Kõks S, Altmäe S, Heinaste E, Vabrit K, Tammekivi V, Hallast P, Koido K, Kurg A, Metspalu A, Vasar E, Vasar V, Shlik J (2005) Association study of 90 candidate gene polymorphisms in panic disorder. Psychiatric Genetics 15:17-24

Raud S, Innos J, Abramov U, Reimets A, Kõks S, Soosaar A, Matsui T, Vasar E. (2005) Targeted invalidation of CCK(2) receptor gene induces anxiolytic-like action in light-dark exploration, but not in fear conditioning test. Psychopharmacology (Berl) 181: 347-357.

Tõnissoo T, Kõks S, Meier R, Raud S, Plaas M, Vasar E, Karis A (2005) Heterozygous mice with Ric-8 mutation exhibit impaired spatial memory and decreased anxiety. Behavioural Brain Research (in press).

Abramov U, Raud S, Kõks S, Innos J, Kurrikoff K, Matsui T, Vasar E (2004) Targeted mutation of CCK2 receptor gene antagonises behavioural changes induced by social isolation in female, but not in male mice. Behavioural Brain Research 155:1-11.

Kingo K, Kõks S, Nikopensius T, Silm H, Vasar E (2004) Polymorphisms in the interleukin-20 gene: relationships to plaque-type psoriasis. Genes and Immunity 5:117-121.

Kurrikoff K, Kõks S, Matsui T, Bourin M, Arend A, Aunapuu M, Vasar E (2004) Deletion of the CCK2 receptor gene reduces mechanical sensitivity and abolishes the development of hyperalgesia in mononeuropathic mice. European Journal of Neuroscience 20:1577-1586.

Kõks S, Kingo K, Ratsep R, Karelson M, Silm H, Vasar E (2004) Combined haplotype analysis of the interleukin-19 and-20 genes: relationship to plaque-type psoriasis. Genes and Immunity 5:662-667

Kõks S, Kurrikoff K, Matsui T, Bourin M, Vasar E (2004) Deletion of the CCK2 receptor abolishes the development of hyperalgesia in mononeuropathic mice. Regulatory Peptides 122:26-26.

Kõks S, Luuk H, Nelovkov A, Areda T, Vasar E (2004) A screen for genes induced in the amygdaloid area during cat odor exposure. Genes Brain and Behavior 3:80-89.

Maron E, Nikopensius T, Kõks S, Altmae S, Heinaste E, Vabrit K, Tammekivi V, Hallast P, Koido K, Kurg A, Metapalu A, Vasar E, Vasar V, Shlik J (2004) Association study of 90 candidate genetic polymorphisms in panic disorder: Positive findings with SNPs in serotonin, cholecystokinin and dopamine related genes. European Neuropsychopharmacology 14:S317-S317.

Vasar E, Abramov U, Raud S, Kurrikoff K, Volke V, Matsui T, Kõks S (2004) CCK2 receptor deficient mice: Evidence for changes in anxiety. Regulatory Peptides 122:45-46.

Kingo K, Kõks S, Silm H, Vasar E (2003) IL-10 promoter polymorphisms influence disease severity and course in psoriasis. Genes and Immunity 4:455-457.

Kõks S (2003) A screen for genes induced in the amygdaloid area of rats during cat odor exposure. European Neuropsychopharmacology 13:S362-S362.

Kõks S, Abramov U, Veraksits A, Bourin M, Matsui T, Vasar E (2003) CCK2 receptor-deficient mice have increased sensitivity of dopamine D-2 receptors. Neuropeptides 37:25-29.

Kõks S, Koido K, Maron E, Nikopensius T, Kurg A, Slik J, Vasar E, Metspalu A (2003) Analysis of single nucleotide polymorphisms in patients with mood disorders. Behavior Genetics 33:709-709.

Luuk H, Kõks S, Nelovkov A, Vasar E (2003) A screen for genes induced in the amygdaloid area during cat odor exposure. Behavior Genetics 33:710-711.

Nelovkov A, Philips MA, Kõks S, Vasar E (2003) Rats with low exploratory activity in the elevated plus-maze have the increased expression of limbic system-associated membrane protein gene in the periaqueductal grey. Neuroscience Letters 352:179-182.

Raud S, Runkorg K, Veraksits A, Reimets A, Nelovkov A, Abramov U, Matsui T, Bourin M, Volke V, Kõks S, Vasar E (2003) Targeted mutation of CCK2 receptor gene modifies the behavioural effects of diazepam in female mice. Psychopharmacology 168:417-425.

Roots K, Kõks S, Kairane C, Salum T, Karelson E, Vasar E, Zilmer M (2003) Na-pump kinetic properties are differently altered in the brain regions of the cholecystokinin(2) receptor-deficient mice. Annals of the New York Academy of Science 986:644-645.

Runkorg K, Veraksits A, Kurrikoff K, Luuk H, Raud S, Abramov U, Matsui T, Bourin M, Kõks S, Vasar E (2003) Distinct changes in the behavioural effects of morphine and naloxone in CCK2 receptor-deficient mice. Behavioural Brain Research 144:125-135.

Vasar E, Kõks S, Abramov U, Innos J, Raud S, Kurrikoff K, Volke V, Bourin M, Matsui T (2003) CCK2 receptor deficient mice: Changes in anxiety and pain sensitivity. European Neuropsychopharmacology 13:S384-S384.

Veraksits A, Runkorg K, Kurrikoff K, Raud S, Abramov U, Matsui T, Bourin M, Kõks S, Vasar E (2003) Altered pain sensitivity and morphine-induced anti-nociception in mice lacking CCK2 receptors. Psychopharmacology 166:168-175.

Kairane C, Roots K, Uusma T, Bogdanovic N, Karelson E, Kõks S, Zilmer M (2002) Regulation of the frontocortical sodium pump by Na+ in Alzheimer's disease: difference from the age-matched control but similarity to the rat model. FEBS Letters 531:241-244.

Kurg A, Nikopensius T, Hallast P, Laan M, Kõks S, Shlik J, Maron E, Vasar E, Metspalu A (2002) Possible association of serotonin 1B receptor and cholecystokinin 1 receptor gene polymorphisms in bipolar and unipolar affective disorder cases in Estonia. American Journal of Human Genetics 71:484-484.

Kõks S, Planken A, Luuk H, Vasar E (2002) Cat odour exposure increases the expression of wolframin gene in the amygdaloid area of rat. Neuroscience Letters 322:116-120.

Kõks S, Vasar E (2002) Deramciclane. Drug Evaluation. Current Opinion in Investigational Drugs 3: 289-294.

Vasar E, Raud S, Veraksits A, Runkorg K, Matsui T, Bourin M, Greengrass CJ, Volke V, Kõks S (2002) Mice lacking CCK2 receptors display reduced anxiety in the plus-maze. European Psychiatry 17:50S-50S.

Kõks S, Beljajev S, Koovit I, Abramov U, Bourin M, Vasar E (2001) 8-OH-DPAT, but not deramciclane, antagonizes the anxiogenic-like action of paroxetine in an elevated plus-maze. Psychopharmacology 153:365-372.

Kõks S, Volke V, Veraksits A, Runkorg K, Sillat T, Abramov U, Bourin M, Huotari M, Mannisto PT, Matsui T, Vasar E (2001) Cholecystokinin(2) receptor-deficient mice display altered function of brain dopaminergic system. Psychopharmacology 158:198-204.

Võikar V, Kõks S, Vasar E, Rauvala H (2001) Strain and gender differences in the behavior of mouse lines commonly used in transgenic studies. Physiology & Behavior 72:271-281.

Kõks S, Mannisto PT, Bourin M, Shlik J, Vasar V, Vasar E (2000) Cholecystokinin-induced anxiety in rats: relevance of pre-experimental stress and seasonal variations. Journal of Psychiatry & Neuroscience 25:33-42.

Kõks S, Bourin M, Voikar V, Soosaar A, Vasar E (1999) Role of CCK in anti-exploratory action of paroxetine, 5-HT reuptake inhibitor. International Journal of Neuropsychopharmacology 2:9-16.

Kõks S, Soosaar A, Voikar V, Bourin M, Vasar E (1999) BOC-CCK-4, CCKB receptor agonist, antagonises anxiolytic-like action of morphine in elevated plus-maze. Neuropeptides 33:63-69.

Võikar V, Soosaar A, Volke V, Kõks S, Bourin M, Mannisto PT, Vasar E (1999) Apomorphine-induced behavioural sensitization in rats: individual differences, role of dopamine and NMDA receptors. European Neuropsychopharmacology 9:507-514.

Kõks S, Soosaar A, Voikar V, Volke V, Ustav M, Mannisto PT, Bourin M, Vasar E (1998) Opioid antagonist naloxone potentiates anxiogenic-like action of cholecystokinin agonists in elevated plus-maze. Neuropeptides 32:235-240.

Volke V, Soosaar A, Kõks S, Vasar E, Mannisto PT (1998) L-arginine abolishes the anxiolytic-like effect of diazepam in the elevated plus-maze test in rats. European Journal of Pharmacology 351:287-290.

Kõks S, Vasar E, Soosaar A, Lang A, Volke V, Voikar V, Bourin M, Mannisto PT (1997) Relation of exploratory behavior of rats in elevated plus-maze to brain receptor binding properties and serum growth hormone levels. European Neuropsychopharmacology 7:289-294.

Volke V, Soosaar A, Kõks S, Bourin M, Mannisto PT, Vasar E (1997) 7-nitroindazole, a nitric oxide synthase inhibitor, has anxiolytic like properties in exploratory models of anxiety. Psychopharmacology 131:399-405.

Volke V, Soosaar A, Kõks S, Bourin M, Mannisto PT, Vasar E (1996) Nitric oxide mediates caerulein-induced suppression of locomotor activity. Neuropeptides 30:323-326.

Lang A, Harro J, Soosaar a, Kõks S, Volke V, Oreland L, Bourin M, Vasar E, Bradwejn J, Mannisto PT (1995) Role of N-Methyl-D-Aspartic Acid and Cholecystokinin Receptors in Apomorphine-Induced Aggressive-Behavior in Rats. Naunyn-Schmiedebergs Archives of Pharmacology 351:363-370.

Peuranen E, Vasar E, Kõks S, Volke V, Lang a, Rauhala P, Mannisto PT (1995) Further-Studies on the Role of Cholecystokinin-a and Cholecystokinin-B Receptors in Secretion of Anterior-Pituitary Hormones in Male-Rats. Neuropeptides 28:1-11.

Volke V, Kõks S, Vasar E, Bourin M, Bradwejn J, Mannisto PT (1995) Inhibition of Nitric-Oxide Synthase Causes Anxiolytic-Like Behavior in an Elevated Plus-Maze. Neuroreport 6:1413-1416.

Lang A, Soosaar A, Kõks S, Volke V, Bourin M, Bradwejn J, Vasar E (1994) Pharmacological Comparison of Antipsychotic-Drugs and Sigma-Antagonists in Rodents. Pharmacology & Toxicology 75:222-227.

Vasar E, Lang A, Harro J, Kõks S, Volke V, Sihver S, Bourin M, Bradwejn J, Mannisto PT (1994) Subdiaphragmatic Vagotomy Does Not Prevent the Anti-Exploratory Effect of Cerulein in the Elevated Plus-Maze. Neuropeptides 26:39-45.

Vasar E, Harro J, Lang A, Soosaar A, Ööpik T, Kõks S, Sihver S, Volke V (1993) Anti-exploratory effect of N-methyl-D-aspartate in elevated plus-maze. Involvement of NMDA and CCK receptors. European Neuropsychopharmacology 3:63-73.

Kaido Kurrikoff, MSc, 2005, superv. Sulev Kõks. CCK2 retseptori geneetiline väljalülitamine vähendab mehaanilist tundlikkust ja pärsib hüperalgeesia teket närvikahjustusega hiirtel. Tartu

Kristel Vabrit, MSc, 2005, superv. Sulev Kõks. Võimalikud seosed tsütokiinide interleukiin 20 ja interleukiin 24 geenide polümorfismide ja naastulise psoriaasi kujunemise vahel. Tartu

Külli Kingo, PhD, 2005, superv. Sulev Kõks. The interleukin-10 family cytokines gene polymorphisms in plaque psoriasis. Tartu

Mario Plaas, MSc, 2005, superv. Sulev Kõks. Alfa-syn Ala30Pro punktmutatsiooniga ja beeta-syn deletsiooniga hiireliinide loomine: uued Parkinsoni haiguse mudelid. Tartu

Ranno Rätsep, MSc, 2005, superv. Sulev Kõks. Interleukiin-19 ja intereleukiin-20 haplotüüpide efektid naastulise psoriaasi avaldumisel. Tartu

Hendrik Luuk, MSc, 2004, superv. Sulev Kõks. Volframiini ja karboksüpeptidaas E koregulatsioon roti mandelkehas vastusena hirmuregulatsioonile ja interaktsioon rakukultuuris. Tartu

Mari-Anne Philips, MSc, 2004, superv. Sulev Kõks. Agressiivsete (SAL) ja mitte-agressiivsete (LAL) hiireliinide geeniekspressiooni diferentsiaalanalüüs hippokampuses.. Tartu

S. Kõks, K. Kingo, E. Vasar, H. Silm “Interleukin-19 subfamily of cytokines”, peatükk raamatus “Cytokine gene polymorphisms in multifactorial conditions”. CRC Press, in press.

S. Kõks, K. Kingo, E. Vasar, H. Silm “Psoriasis and cytokine polymorphisms”, peatükk raamatus “Cytokine gene polymorphisms in multifactorial conditions”. CRC Press, in press.

Abramov U, Vasar E, Kõks S. (2005) Altered behavioural effects of ethanol and increased voluntary ethanol consumption in mice lacking cck2 receptors. Behavioral Pharmacology 16 1:S19.

Areda T, Kõks S, Philips MA, Vasar E, Karis A, Asser T (2005) Alterations in opioid system of the rat brain after cat odor exposure. Neuroscience Letters 377:136-139.

Kingo K, Rätsep R, Kõks S, Karelson M, Silm H, Vasar E (2005) Influence of genetic polymorphisms on interleukin-10 mRNA expression and psoriasis susceptibility. Journal of Dermatological Science 37:111-113.

Koido K, Kõks S, Nikopensius T, Maron E, Altme S, Heinaste E, Vabrit K, Tammekivi V, Hallast P, Kurg A, Shlik J, Vasar V, Metspalu A, Vasar E (2005) Polymorphisms in wolframin (WFS1) gene are possibly related to increased risk for mood disorders. International Journal of Neuropsychopharmacology 8:235-244.

Kõks S, Kingo K, Vabrit K, Rätsep R, Karelson M, Silm H, Vasar E. (2005) Possible relations between the polymorphisms of the cytokines IL 19, IL 20 and IL 24 and plaque-type psoriasis. Genes and Immunity 6:407-415.

Kõks S, Nikopensius T, Koido K, Maron E, Altmäe S, Heinaste E, Vabrit K, Tammekivi V, Hallast P, Kurg A, Shlik J, Vasar V, Metspalu A, Vasar E. (2005) Analysis of SNP profiles in patients with major depressive disorder. International Journal of Neuropsychopharmacology. (In press, doi:10.1017/ S1461145705005468).

Luuk H, Toots U, Kõks S, Vasar E (2005) N-terminal domain of Wolframin interacts with carboxypeptidase E. European Neuropsychopharmacology 15:S5-S6.

Maron E, Kõks S, Nikopensius T, Altmae S, Heinaste E, Vabrit K, Tammekivi V, Hallast P, Koido K, Kurg A, Shlik J, Vasar V, Metspalu A, Vasar E (2005) Association and haplotype analaysis of 90 single-nucleotide polymorphisms in mood disorders. European Neuropsychopharmacology 15:S55-S56.

Maron E, Nikopensius T, Kõks S, Altmäe S, Heinaste E, Vabrit K, Tammekivi V, Hallast P, Koido K, Kurg A, Metspalu A, Vasar E, Vasar V, Shlik J (2005) Association study of 90 candidate gene polymorphisms in panic disorder. Psychiatric Genetics 15:17-24

Raud S, Innos J, Abramov U, Reimets A, Kõks S, Soosaar A, Matsui T, Vasar E. (2005) Targeted invalidation of CCK(2) receptor gene induces anxiolytic-like action in light-dark exploration, but not in fear conditioning test. Psychopharmacology (Berl) 181: 347-357.

Tõnissoo T, Kõks S, Meier R, Raud S, Plaas M, Vasar E, Karis A (2005) Heterozygous mice with Ric-8 mutation exhibit impaired spatial memory and decreased anxiety. Behavioural Brain Research (in press).

Abramov U, Raud S, Kõks S, Innos J, Kurrikoff K, Matsui T, Vasar E (2004) Targeted mutation of CCK2 receptor gene antagonises behavioural changes induced by social isolation in female, but not in male mice. Behavioural Brain Research 155:1-11.

Kingo K, Kõks S, Nikopensius T, Silm H, Vasar E (2004) Polymorphisms in the interleukin-20 gene: relationships to plaque-type psoriasis. Genes and Immunity 5:117-121.

Kurrikoff K, Kõks S, Matsui T, Bourin M, Arend A, Aunapuu M, Vasar E (2004) Deletion of the CCK2 receptor gene reduces mechanical sensitivity and abolishes the development of hyperalgesia in mononeuropathic mice. European Journal of Neuroscience 20:1577-1586.

Kõks S, Kingo K, Ratsep R, Karelson M, Silm H, Vasar E (2004) Combined haplotype analysis of the interleukin-19 and-20 genes: relationship to plaque-type psoriasis. Genes and Immunity 5:662-667

Kõks S, Kurrikoff K, Matsui T, Bourin M, Vasar E (2004) Deletion of the CCK2 receptor abolishes the development of hyperalgesia in mononeuropathic mice. Regulatory Peptides 122:26-26.

Kõks S, Luuk H, Nelovkov A, Areda T, Vasar E (2004) A screen for genes induced in the amygdaloid area during cat odor exposure. Genes Brain and Behavior 3:80-89.

Maron E, Nikopensius T, Kõks S, Altmae S, Heinaste E, Vabrit K, Tammekivi V, Hallast P, Koido K, Kurg A, Metapalu A, Vasar E, Vasar V, Shlik J (2004) Association study of 90 candidate genetic polymorphisms in panic disorder: Positive findings with SNPs in serotonin, cholecystokinin and dopamine related genes. European Neuropsychopharmacology 14:S317-S317.

Vasar E, Abramov U, Raud S, Kurrikoff K, Volke V, Matsui T, Kõks S (2004) CCK2 receptor deficient mice: Evidence for changes in anxiety. Regulatory Peptides 122:45-46.

Kingo K, Kõks S, Silm H, Vasar E (2003) IL-10 promoter polymorphisms influence disease severity and course in psoriasis. Genes and Immunity 4:455-457.

Kõks S (2003) A screen for genes induced in the amygdaloid area of rats during cat odor exposure. European Neuropsychopharmacology 13:S362-S362.

Kõks S, Abramov U, Veraksits A, Bourin M, Matsui T, Vasar E (2003) CCK2 receptor-deficient mice have increased sensitivity of dopamine D-2 receptors. Neuropeptides 37:25-29.

Kõks S, Koido K, Maron E, Nikopensius T, Kurg A, Slik J, Vasar E, Metspalu A (2003) Analysis of single nucleotide polymorphisms in patients with mood disorders. Behavior Genetics 33:709-709.

Luuk H, Kõks S, Nelovkov A, Vasar E (2003) A screen for genes induced in the amygdaloid area during cat odor exposure. Behavior Genetics 33:710-711.

Nelovkov A, Philips MA, Kõks S, Vasar E (2003) Rats with low exploratory activity in the elevated plus-maze have the increased expression of limbic system-associated membrane protein gene in the periaqueductal grey. Neuroscience Letters 352:179-182.

Raud S, Runkorg K, Veraksits A, Reimets A, Nelovkov A, Abramov U, Matsui T, Bourin M, Volke V, Kõks S, Vasar E (2003) Targeted mutation of CCK2 receptor gene modifies the behavioural effects of diazepam in female mice. Psychopharmacology 168:417-425.

Roots K, Kõks S, Kairane C, Salum T, Karelson E, Vasar E, Zilmer M (2003) Na-pump kinetic properties are differently altered in the brain regions of the cholecystokinin(2) receptor-deficient mice. Annals of the New York Academy of Science 986:644-645.

Runkorg K, Veraksits A, Kurrikoff K, Luuk H, Raud S, Abramov U, Matsui T, Bourin M, Kõks S, Vasar E (2003) Distinct changes in the behavioural effects of morphine and naloxone in CCK2 receptor-deficient mice. Behavioural Brain Research 144:125-135.

Vasar E, Kõks S, Abramov U, Innos J, Raud S, Kurrikoff K, Volke V, Bourin M, Matsui T (2003) CCK2 receptor deficient mice: Changes in anxiety and pain sensitivity. European Neuropsychopharmacology 13:S384-S384.

Veraksits A, Runkorg K, Kurrikoff K, Raud S, Abramov U, Matsui T, Bourin M, Kõks S, Vasar E (2003) Altered pain sensitivity and morphine-induced anti-nociception in mice lacking CCK2 receptors. Psychopharmacology 166:168-175.

Kairane C, Roots K, Uusma T, Bogdanovic N, Karelson E, Kõks S, Zilmer M (2002) Regulation of the frontocortical sodium pump by Na+ in Alzheimer's disease: difference from the age-matched control but similarity to the rat model. FEBS Letters 531:241-244.

Kurg A, Nikopensius T, Hallast P, Laan M, Kõks S, Shlik J, Maron E, Vasar E, Metspalu A (2002) Possible association of serotonin 1B receptor and cholecystokinin 1 receptor gene polymorphisms in bipolar and unipolar affective disorder cases in Estonia. American Journal of Human Genetics 71:484-484.

Kõks S, Planken A, Luuk H, Vasar E (2002) Cat odour exposure increases the expression of wolframin gene in the amygdaloid area of rat. Neuroscience Letters 322:116-120.

Kõks S, Vasar E (2002) Deramciclane. Drug Evaluation. Current Opinion in Investigational Drugs 3: 289-294.

Vasar E, Raud S, Veraksits A, Runkorg K, Matsui T, Bourin M, Greengrass CJ, Volke V, Kõks S (2002) Mice lacking CCK2 receptors display reduced anxiety in the plus-maze. European Psychiatry 17:50S-50S.

Kõks S, Beljajev S, Koovit I, Abramov U, Bourin M, Vasar E (2001) 8-OH-DPAT, but not deramciclane, antagonizes the anxiogenic-like action of paroxetine in an elevated plus-maze. Psychopharmacology 153:365-372.

Kõks S, Volke V, Veraksits A, Runkorg K, Sillat T, Abramov U, Bourin M, Huotari M, Mannisto PT, Matsui T, Vasar E (2001) Cholecystokinin(2) receptor-deficient mice display altered function of brain dopaminergic system. Psychopharmacology 158:198-204.

Võikar V, Kõks S, Vasar E, Rauvala H (2001) Strain and gender differences in the behavior of mouse lines commonly used in transgenic studies. Physiology & Behavior 72:271-281.

Kõks S, Mannisto PT, Bourin M, Shlik J, Vasar V, Vasar E (2000) Cholecystokinin-induced anxiety in rats: relevance of pre-experimental stress and seasonal variations. Journal of Psychiatry & Neuroscience 25:33-42.

Kõks S, Bourin M, Voikar V, Soosaar A, Vasar E (1999) Role of CCK in anti-exploratory action of paroxetine, 5-HT reuptake inhibitor. International Journal of Neuropsychopharmacology 2:9-16.

Kõks S, Soosaar A, Voikar V, Bourin M, Vasar E (1999) BOC-CCK-4, CCKB receptor agonist, antagonises anxiolytic-like action of morphine in elevated plus-maze. Neuropeptides 33:63-69.

Võikar V, Soosaar A, Volke V, Kõks S, Bourin M, Mannisto PT, Vasar E (1999) Apomorphine-induced behavioural sensitization in rats: individual differences, role of dopamine and NMDA receptors. European Neuropsychopharmacology 9:507-514.

Kõks S, Soosaar A, Voikar V, Volke V, Ustav M, Mannisto PT, Bourin M, Vasar E (1998) Opioid antagonist naloxone potentiates anxiogenic-like action of cholecystokinin agonists in elevated plus-maze. Neuropeptides 32:235-240.

Volke V, Soosaar A, Kõks S, Vasar E, Mannisto PT (1998) L-arginine abolishes the anxiolytic-like effect of diazepam in the elevated plus-maze test in rats. European Journal of Pharmacology 351:287-290.

Kõks S, Vasar E, Soosaar A, Lang A, Volke V, Voikar V, Bourin M, Mannisto PT (1997) Relation of exploratory behavior of rats in elevated plus-maze to brain receptor binding properties and serum growth hormone levels. European Neuropsychopharmacology 7:289-294.

Volke V, Soosaar A, Kõks S, Bourin M, Mannisto PT, Vasar E (1997) 7-nitroindazole, a nitric oxide synthase inhibitor, has anxiolytic like properties in exploratory models of anxiety. Psychopharmacology 131:399-405.

Volke V, Soosaar A, Kõks S, Bourin M, Mannisto PT, Vasar E (1996) Nitric oxide mediates caerulein-induced suppression of locomotor activity. Neuropeptides 30:323-326.

Lang A, Harro J, Soosaar a, Kõks S, Volke V, Oreland L, Bourin M, Vasar E, Bradwejn J, Mannisto PT (1995) Role of N-Methyl-D-Aspartic Acid and Cholecystokinin Receptors in Apomorphine-Induced Aggressive-Behavior in Rats. Naunyn-Schmiedebergs Archives of Pharmacology 351:363-370.

Peuranen E, Vasar E, Kõks S, Volke V, Lang a, Rauhala P, Mannisto PT (1995) Further-Studies on the Role of Cholecystokinin-a and Cholecystokinin-B Receptors in Secretion of Anterior-Pituitary Hormones in Male-Rats. Neuropeptides 28:1-11.

Volke V, Kõks S, Vasar E, Bourin M, Bradwejn J, Mannisto PT (1995) Inhibition of Nitric-Oxide Synthase Causes Anxiolytic-Like Behavior in an Elevated Plus-Maze. Neuroreport 6:1413-1416.

Lang A, Soosaar A, Kõks S, Volke V, Bourin M, Bradwejn J, Vasar E (1994) Pharmacological Comparison of Antipsychotic-Drugs and Sigma-Antagonists in Rodents. Pharmacology & Toxicology 75:222-227.

Vasar E, Lang A, Harro J, Kõks S, Volke V, Sihver S, Bourin M, Bradwejn J, Mannisto PT (1994) Subdiaphragmatic Vagotomy Does Not Prevent the Anti-Exploratory Effect of Cerulein in the Elevated Plus-Maze. Neuropeptides 26:39-45.

Vasar E, Harro J, Lang A, Soosaar A, Ööpik T, Kõks S, Sihver S, Volke V (1993) Anti-exploratory effect of N-methyl-D-aspartate in elevated plus-maze. Involvement of NMDA and CCK receptors. European Neuropsychopharmacology 3:63-73.